Difference between revisions of "Tafasitamab (Monjuvi)"
Jump to navigation
Jump to search
Warner-admin (talk | contribs) m (Text replacement - "https://ascopubs.org/doi/full/10.1200" to "https://doi.org/10.1200") |
m |
||
Line 2: | Line 2: | ||
Anti-CD19 antibody with an engineered Fc region to enhance Fcγ receptor binding affinity | Anti-CD19 antibody with an engineered Fc region to enhance Fcγ receptor binding affinity | ||
− | == | + | ==Diseases for which it is used== |
− | + | *[[Diffuse large B-cell lymphoma]] | |
− | # | + | *[[Transformed lymphoma]] |
+ | # '''Abstract:''' Kami J. Maddocks, Eva González Barca, Wojciech Jurczak, Anna Marina Liberati, Johannes Duell, Zsolt Nagy, Tomáš Papajík, Marc Andre, Nagesh Kalakonda, Martin H. Dreyling, Pier Luigi Zinzani, Sumeet Vijay Ambarkhane, Johannes Weirather, and Gilles A. Salles. L-mind: MOR208 combined with lenalidomide (LEN) in patients with relapsed or refractory diffuse large b-cell lymphoma (R-R DLBCL)—A single-arm phase II study. Journal of Clinical Oncology 2017 35:15_suppl, 7514-7514 [https://doi.org/10.1200/JCO.2017.35.15_suppl.7514 link to abstract] | ||
− | == | + | ==History of changes in FDA indication== |
− | + | *7/31/2020: Granted accelerated approval in combination with lenalidomide for adult patients with relapsed or refractory [[Diffuse large B-cell lymphoma|diffuse large B-cell lymphoma (DLBCL) not otherwise specified]], including [[Transformed lymphoma|DLBCL arising from low grade lymphoma]], and who are not eligible for autologous stem cell transplant. | |
==Also known as== | ==Also known as== | ||
− | *'''Code names:''' MOR00208, XmAb5574 | + | *'''Code names:''' MOR208, MOR00208, XmAb5574 |
+ | *'''Generic name:''' tafasitamab-cxix | ||
+ | *'''Brand name:''' Monjuvi | ||
[[Category:Drugs]] | [[Category:Drugs]] | ||
[[Category:Intravenous medications]] | [[Category:Intravenous medications]] | ||
− | |||
[[Category:Anti-CD19 antibodies]] | [[Category:Anti-CD19 antibodies]] | ||
− | |||
[[Category:Diffuse large B-cell lymphoma medications]] | [[Category:Diffuse large B-cell lymphoma medications]] | ||
+ | [[Category:Transformed lymphoma medications]] | ||
− | [[Category: | + | [[Category:FDA approved in 2020]] |
Revision as of 22:23, 3 August 2020
Mechanism of action
Anti-CD19 antibody with an engineered Fc region to enhance Fcγ receptor binding affinity
Diseases for which it is used
- Abstract: Kami J. Maddocks, Eva González Barca, Wojciech Jurczak, Anna Marina Liberati, Johannes Duell, Zsolt Nagy, Tomáš Papajík, Marc Andre, Nagesh Kalakonda, Martin H. Dreyling, Pier Luigi Zinzani, Sumeet Vijay Ambarkhane, Johannes Weirather, and Gilles A. Salles. L-mind: MOR208 combined with lenalidomide (LEN) in patients with relapsed or refractory diffuse large b-cell lymphoma (R-R DLBCL)—A single-arm phase II study. Journal of Clinical Oncology 2017 35:15_suppl, 7514-7514 link to abstract
History of changes in FDA indication
- 7/31/2020: Granted accelerated approval in combination with lenalidomide for adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL) not otherwise specified, including DLBCL arising from low grade lymphoma, and who are not eligible for autologous stem cell transplant.
Also known as
- Code names: MOR208, MOR00208, XmAb5574
- Generic name: tafasitamab-cxix
- Brand name: Monjuvi